ValuEngine upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a report released on Monday.
Other equities analysts also recently issued research reports about the company. SunTrust Banks reiterated a buy rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a report on Friday, March 9th. Piper Jaffray reiterated a buy rating and issued a $22.75 price objective (down previously from $39.00) on shares of CRISPR Therapeutics in a report on Wednesday, January 10th. BidaskClub upgraded CRISPR Therapeutics from a hold rating to a buy rating in a report on Thursday, January 4th. TheStreet upgraded CRISPR Therapeutics from a d+ rating to a c rating in a report on Friday, March 16th. Finally, Oppenheimer reiterated a hold rating on shares of CRISPR Therapeutics in a report on Thursday, December 21st. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $63.95.
CRSP traded up $3.77 during trading on Monday, reaching $46.44. The stock had a trading volume of 1,202,698 shares, compared to its average volume of 1,095,946. The company has a market cap of $2,082.42, a price-to-earnings ratio of -24.95 and a beta of 3.56. CRISPR Therapeutics has a one year low of $13.50 and a one year high of $61.24.
Several large investors have recently modified their holdings of the company. Wells Fargo & Company MN increased its holdings in shares of CRISPR Therapeutics by 17.2% during the fourth quarter. Wells Fargo & Company MN now owns 21,517 shares of the company’s stock valued at $505,000 after acquiring an additional 3,165 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 22.8% during the fourth quarter. ARK Investment Management LLC now owns 31,388 shares of the company’s stock valued at $737,000 after acquiring an additional 5,833 shares in the last quarter. Creative Planning bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $243,000. Paloma Partners Management Co bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $290,000. Finally, D.A. Davidson & CO. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $370,000. Hedge funds and other institutional investors own 26.61% of the company’s stock.
WARNING: “CRISPR Therapeutics (CRSP) Upgraded by ValuEngine to “Hold”” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3335519/crispr-therapeutics-crsp-upgraded-by-valuengine-to-hold.html.
About CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.